BHC — Bausch Health Companies Inc.

NYSE · Health Care · Pharmaceuticals · CIK 885590 ·
Last close
$6.89
Market Cap
$2.57B
52W High
$6.91
52W Low
$4.33
ADV30
3,659,541
Next earnings
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Jun 2026
Mar 2026 2,524,000,000 1,786,000,000 521,000,000 -1,423,000,000 24,498,000,000 1,299,000,000 25,580,000,000
Dec 2025 2,796,000,000 1,998,000,000 829,000,000 -112,000,000 26,366,000,000 1,309,000,000 25,989,000,000
Sep 2025 2,681,000,000 1,931,000,000 636,000,000 179,000,000 26,824,000,000 1,308,000,000 26,468,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$1,419,000,000
Investing CF
$-604,000,000
Financing CF
$-696,000,000
CapEx
$-430,000,000
Dividends Paid
$0
Buybacks
EPS Diluted TTM
$-3.24
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-11,090,000,000
Inventory
$1,601,000,000
Receivables
$2,191,000,000
ST Investments
EBIT TTM
$736,000,000
Pretax Income TTM
$-940,000,000
Interest Exp TTM
$1,676,000,000
Analysts
7

Yahoo Snapshot (yfinance, live)

Total Revenue
$10,853,000,192
EBITDA
$3,854,000,128
Free Cash Flow
$1,123,500,032
Enterprise Value
$22,725,058,560
Total Cash
$1,299,000,064
Total Debt
$20,795,000,832
Shares Out
373,475,644
Trailing EPS
$-2.94
Book Value
$-5.51
ROE
ROA
5.9%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 10,266,000,000 2,185,000,000 157,000,000 26,366,000,000 25,989,000,000 1,400,000,000
Dec 2024 9,625,000,000 1,854,000,000 -46,000,000 26,523,000,000 26,845,000,000 1,597,000,000
Dec 2023 8,757,000,000 1,600,000,000 -592,000,000 27,350,000,000 27,432,000,000 1,032,000,000
Dec 2022 8,124,000,000 1,391,000,000 -225,000,000 25,686,000,000 25,426,000,000 -728,000,000

TTM Snapshot

Revenues TTM
$8,905,000,000
NetIncome TTM
$124,000,000
OpCashFlow TTM
$0
Assets (Latest)
$26,523,000,000
Forward EPS
$3.88

Max Pain — expiry 2026-08-21

max pain strike: $5.00 · spot: $6.89 · call oi: 15,253 · put oi: 1,679
Expected Move to 2026-08-21: ±$0.95 (13.79%) — implied range $5.94$7.84 · ATM straddle on $7.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
IMNM Immunome Inc. $2.58B $22.76
SUPN SUPERNUS PHARMACEUTICALS, INC. $2.59B $44.63
TRVI Trevi Therapeutics, Inc. $2.59B $18.25
ATAI AtaiBeckley Inc. $2.66B $7.18
RARE Ultragenyx Pharmaceutical Inc. $2.45B $24.91

News headlines (Yahoo Finance, 1h cache)

Bausch Health (BHC) Rockets 28% as Q2 Turnaround Fuels Recovery Outlook
2026-07-31 04:03 · Yahoo
Sector Update: Healthcare Stocks Decline Late Afternoon
2026-07-30 19:46 · Yahoo
BHC Q2 Earnings Beat Estimates on Salix and Solta Growth, '26 View Raised
2026-07-30 16:33 · Yahoo
Bausch Health Companies Inc. Q2 2026 Earnings Call Summary
2026-07-30 12:30 · Yahoo
Bausch Health Cos Q2 Earnings Call Highlights
2026-07-30 01:04 · Yahoo
Bausch Health (BHC) Q2 Earnings and Revenues Beat Estimates
2026-07-30 00:35 · Yahoo
Bausch (BHC) Reports Q2 Earnings: What Key Metrics Have to Say
2026-07-29 23:30 · Yahoo
BAUSCH HEALTH ANNOUNCES SECOND QUARTER 2026 RESULTS, RAISES GUIDANCE
2026-07-29 20:05 · Yahoo
(Pr)ELIDEL® (pimecrolimus) cream Now Reimbursed Under Alberta's Public Drug Plan for Eligible Patients with Mild to Moderate Atopic Dermatitis
2026-07-28 12:00 · Yahoo
Bausch Health’s (BHC) Canadian Subsidiary Lists PrOKEDI Dosages in RAMQ Formulary
2026-07-12 17:21 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.